Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults

NCT02014727 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

OTHER_GOV

Sponsor class

Conditions

Malaria, Falciparum

Interventions

BIOLOGICAL: Group A1 : 50µg AMA1-DiCo + Alhydrogel
BIOLOGICAL: Group A2 : 50 µg AMA1-DiCo+ GLA-SE
BIOLOGICAL: Group B2 : Placebo

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]